AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.021

-0.001-4.55%

Volume:2.08M

Turnover:45.63K

Market Cap:74.43M

PE:-1.14

High:0.023

Open:0.022

Low:0.021

Close:0.022

52wk High:0.040

52wk Low:0.017

Shares:3.54B

Float Shares:2.86B

Volume Ratio:0.72

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-109.20%

ROA:-27.70%

PB:1.66

PE(LYR):-1.14

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Radiopharm Theranostics posts HY net cash outflows from operating activities of USD 22.67 million

Press Release: Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

Radiopharm Theranostics Slides As Insider Purchases Lose Another AU$25k

Simply Wall St.

Rad Increases Ownership in Radiopharm Ventures to 87.5%

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAD.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.021,"timestamp":1770354720000,"preClose":0.022,"halted":0,"volume":2082734,"delay":0,"changeRate":-0.04545454545454534,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":2856071021,"shares":3544216000,"eps":-0.018424,"marketStatus":"Market Closed","change":-0.001,"latestTime":"02-06 16:12:00 AEDT","open":0.022,"high":0.023,"low":0.021,"amount":45631,"amplitude":0.090909,"askPrice":0.023,"askSize":671459,"bidPrice":0.021,"bidSize":1135739,"shortable":3,"etf":0,"ttmEps":-0.018424,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770591600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.022,"openAndCloseTimeList":[[1770332400000,1770354000000]],"volumeRatio":0.7192709314961583,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":2856071021,"roa":"-27.70%","roe":"-109.20%","lyrEps":-0.018424,"volumeRatio":0.7192709314961583,"shares":3544216000,"dividePrice":0,"high":0.023,"amplitude":0.090909,"preClose":0.022,"low":0.021,"week52Low":0.017,"pbRate":"1.66","psRate":"5.95","week52High":0.04,"institutionHeld":0,"latestPrice":0.021,"committee":0.256906,"eps":-0.018424,"divideRate":0,"volume":2082734,"delay":0,"ttmEps":-0.018424,"open":0.022,"prevYearClose":0.025,"prevWeekClose":0.021,"prevMonthClose":0.021,"prevQuarterClose":0.025,"fiveDayClose":0.021,"twentyDayClose":0.025,"sixtyDayClose":0.023,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606158327","title":"Radiopharm Theranostics posts HY net cash outflows from operating activities of USD 22.67 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2606158327","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606158327?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:00","pubTimestamp":1769601655,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd. reported its financial results for the first half of fiscal 2026 ended December 31, 2025. The company recorded net cash outflows from operating activities of USD 22.67 million during the period. Cash and cash equivalents stood at USD 34.52 million, providing a runway into 2027 to support the advancement of its radiotherapeutic pipeline through key clinical and regulatory milestones. In October 2025, Radiopharm Theranostics secured commitments to raise approximately USD 35 million via private placement from international and Australian institutional and industry investors. Payments to related parties during the half-year period encompassed remuneration for director fees to executive and non-executive directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL4XCG9v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","BK4112","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014021.USD","LU0314104364.USD","LU2210150020.SGD","BK7067","IE00B3QW5Z07.USD","BK4585","RAD.AU","LU2095319765.USD","BK4588","SG9999014013.SGD","NDAQ"],"gpt_icon":0},{"id":"2606715341","title":"Press Release: Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2606715341","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606715341?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:00","pubTimestamp":1769601600,"startTime":"0","endTime":"0","summary":"Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases. Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026. Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milestones. RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of the molecule in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins. RAD 101 has received U.S. Food and Drug Administration  Fast Track Designation to expedite the review process and help bring the novel imaging small molecule to the over 300,000 patients diagnosed annually in the U.S. with cerebral metastases. The study is cur","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","IE0009354923.USD","RAD.AU","SOC","BK7067","ODD","DSMC","BK4213"],"gpt_icon":0},{"id":"2605257444","title":"Radiopharm Theranostics Slides As Insider Purchases Lose Another AU$25k","url":"https://stock-news.laohu8.com/highlight/detail?id=2605257444","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605257444?lang=en_us&edition=fundamental","pubTime":"2026-01-23 07:39","pubTimestamp":1769125188,"startTime":"0","endTime":"0","summary":"The recent 12% drop in Radiopharm Theranostics Limited's ( ASX:RAD ) stock could come as a blow to insiders who...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rad/radiopharm-theranostics-shares/news/radiopharm-theranostics-slides-as-insider-purchases-lose-ano","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rad/radiopharm-theranostics-shares/news/radiopharm-theranostics-slides-as-insider-purchases-lose-ano","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2602140385","title":"Rad Increases Ownership in Radiopharm Ventures to 87.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602140385","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602140385?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:08","pubTimestamp":1768219689,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":13,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RAD.AU\",params:#limit:6,delay:true,,,undefined,":[]}}